Progress in the treatment of relapsed/refractory follicular lymphoma
10.3760/cma.j.cn115356-20211206-00284
- VernacularTitle:复发难治滤泡淋巴瘤治疗进展
- Author:
Zhijuan LIN
1
;
Bing XU
Author Information
1. 厦门大学附属第一医院血液科，厦门 361003
- Keywords:
Lymphoma, follicular;
Recurrence;
Refractory;
Molecular targeted therapy;
Antibodies, bispecific;
Chimeric antigen receptor T-cell
- From:
Journal of Leukemia & Lymphoma
2022;31(1):16-19
- CountryChina
- Language:Chinese
-
Abstract:
Follicular lymphoma (FL) is the most common indolent B-cell lymphoma. Although patients with FL generally have a good prognosis, the treatment of relapsed/refractory FL remains a challenge. The 63rd American Society of Hematology (ASH) Annual Meeting announced the latest updates on relapsed/refractory FL, including the usage of targeted therapy, bio-specific antibodies and chimeric antigen receptor T-cell (CAR-T) therapy. This article provides an overview of the updates in combination with the reports presented at the ASH Annual Meeting.
